What is Nuclera?
Founded in 2013 by four PhD students from the University of Cambridge, Nuclera addresses the historical inaccessibility of biological research tools. The company's core innovation is its eProtein desktop bioprinting technology, designed to empower researchers and scientists with streamlined, next-day access to proteins. This democratizes access to essential biological components, accelerating discovery and development in life sciences. Headquartered in Cambridge, UK, Nuclera is positioned at the forefront of biotech innovation, aiming to revolutionize how biological experiments are conducted.
How much funding has Nuclera raised?
Nuclera has raised a total of $157.6M across 5 funding rounds:
Series A
$11.2M
Series B
$58M
Grant
$1.4M
Series C
$75M
Series C
$12M
Series A (2018): $11.2M with participation from RT Partners
Series B (2022): $58M led by M&G, E Ink, Future Planet Capital, Verve Ventures, Amadeus Capital Partners, Jonathan Milner, and RT Partners
Grant (2024): $1.4M supported by UK Research & Innovation
Series C (2024): $75M featuring Elevage Medical Technologies, British Patient Capital, Patient Square Capital, and Cambridge Innovation Capital
Series C (2026): $12M backed by British Business Bank, Elevage Medical Technologies, and G K Goh Holdings
Key Investors in Nuclera
Amadeus Capital Partners
Amadeus Capital Partners is a London-based global technology venture capital firm that invests in high-growth companies from seed to later stages across sectors such as artificial intelligence, digital health, cybersecurity, enterprise software, fintech, and deep tech.
UK Research & Innovation
UK Research & Innovation, headquartered in Swindon, United Kingdom, is a non-departmental public body that works in partnership with universities, research organizations, businesses, charities, and government to create the best possible environment for research and innovation to flourish, ensuring the UK remains a world-leader in science and research.
Elevage Medical Technologies
Elevage Medical Technologies supports medical technology companies, including devices, tools, diagnostics, and tech-enabled services that improve health outcomes and quality of life for patients. Through capital investment and strategic operational support, they strive to accelerate innovation in the medical technology space.
What's next for Nuclera?
With the recent influx of major strategic investment, Nuclera is poised for significant advancements. The company's focus on making biology accessible through its proprietary bioprinting technology suggests a strategic push towards scaling production, enhancing research capabilities, and expanding its market reach. This capital infusion will likely support further research and development, bolster manufacturing capacity, and potentially facilitate strategic partnerships within the enterprise-level biotechnology and pharmaceutical sectors. Nuclera's trajectory indicates a strong commitment to innovation and a clear vision for transforming biological research accessibility.
See full Nuclera company page
